Does UnitedHealthcare Cover Skyrizi for Ulcerative Colitis?

If your gastroenterologist has prescribed Skyrizi (risankizumab) for ulcerative colitis and you carry UnitedHealthcare coverage, the practical question is whether your plan will pay and what you have to do first. The short answer is that UnitedHealthcare generally does cover Skyrizi for moderately to severely active ulcerative colitis, but coverage is gated behind prior authorization and, for many plans, step therapy through preferred agents. Because the ulcerative colitis indication is recent, Skyrizi tends to sit later in the treatment sequence, so the strength of your prior-treatment documentation often decides whether your request clears on the first pass or ends up in an appeal. This guide maps how UnitedHealthcare and its pharmacy manager, OptumRx, typically handle Skyrizi for ulcerative colitis.

Where Skyrizi Sits in Ulcerative Colitis Treatment

Skyrizi is the brand name for risankizumab, an interleukin-23 antagonist that selectively blocks the IL-23 p19 subunit. The FDA approved Skyrizi for moderately to severely active ulcerative colitis in adults on June 18, 2024, making it the first IL-23 specific inhibitor approved for both ulcerative colitis and Crohn's disease. The approval rested on two phase 3 trials. In the INSPIRE induction study, clinical remission at week 12 reached 20.3% with risankizumab versus 6.2% with placebo, and enrolled patients had inadequate response or intolerance to conventional or advanced therapies. Because the indication is newer, payers commonly position Skyrizi after other biologics, which shapes how UnitedHealthcare reviews it.

Does UnitedHealthcare Cover Skyrizi for Ulcerative Colitis

UnitedHealthcare does include Skyrizi for ulcerative colitis among the products its plans can cover, and OptumRx, the pharmacy benefit manager, issued a clinical update recognizing the new ulcerative colitis indication. Coverage is never automatic. UnitedHealthcare's own prior authorization policy for Skyrizi requires a documented diagnosis of moderately to severely active ulcerative colitis and that the drug be prescribed by or in consultation with a gastroenterologist. The policy also states that Skyrizi cannot be approved when used in combination with another targeted immunomodulator such as vedolizumab, mirikizumab, upadacitinib, or ustekinumab. Whether your specific plan covers it, and on what tier, depends on your benefit documents, so confirm the details for your member ID rather than assuming.

Prior Authorization and Step Therapy Expectations

Expect a prior authorization review before any Skyrizi claim is paid, and budget time for it. Standard determinations are often issued within roughly two weeks, while urgent requests can be expedited. Many UnitedHealthcare plans layer step therapy on top of prior authorization, meaning you may need to show that you tried and did not respond to one or more preferred therapies, frequently a tumor necrosis factor inhibitor, before Skyrizi is approved. A common reason these requests are denied is missing documentation of which treatments were tried, for how long, and why they failed or could not be tolerated. Step therapy rules vary by plan and by state, and some states grant the right to request an exception when a required step is medically inappropriate.

How the Benefit Split and Dosing Affect Coverage

Skyrizi for ulcerative colitis uses a two-phase regimen, and the split matters for which benefit pays. The label specifies a 1,200 mg intravenous induction dose given at weeks 0, 4, and 8, followed by 180 mg or 360 mg subcutaneous maintenance every 8 weeks. The intravenous induction is frequently billed under the medical benefit, while the self-injected maintenance pen may run through the pharmacy benefit and Optum Specialty Pharmacy. UnitedHealthcare's policy authorizes coverage for 12 months at a time and requires documentation of a positive clinical response to continue therapy at reauthorization. Knowing whether your induction and maintenance fall under separate benefits helps you anticipate two distinct authorizations and avoid a gap between phases.

Building a Clean Approval or a Strong Appeal

The most reliable way to clear a UnitedHealthcare Skyrizi review is a complete prior-treatment record. Document each ulcerative colitis therapy you have tried, the dates and duration, and the specific reason it was stopped, whether that was inadequate response, loss of response, or intolerance. This evidence is also what powers an appeal if the first request is denied, since risankizumab showed benefit over placebo in patients with prior inadequate response to advanced therapy, a point your gastroenterologist can cite in a medical-necessity letter. Where step therapy seems clinically inappropriate, ask your prescriber to request an exception with supporting rationale. Gastroenterology groups note that risankizumab is now part of the evolving moderate-to-severe ulcerative colitis treatment paradigm, which strengthens the case that it is a reasonable option once preferred agents have failed.

Conclusion

UnitedHealthcare generally covers Skyrizi for moderately to severely active ulcerative colitis, but it treats the drug as a prior-authorization product and, on many plans, a step-therapy option that follows preferred biologics. The recency of the ulcerative colitis indication means reviewers lean heavily on your documented treatment history, so the cleanest path to approval is a thorough record of what you tried and why it did not work. Verify your own formulary, tier, and benefit split through your plan documents or member services, confirm whether induction and maintenance run through different benefits, and have your gastroenterologist anchor the request in the diagnosis, the prior-treatment record, and the clinical evidence. That preparation is what separates a smooth first-pass approval from a drawn-out appeal.